cytosar 500 mg
pfizer europe ma eeig, belgicko - cytarabín - 44 - cytostatica
plerixafor onkogen 20 mg/ml injekčný roztok
onkogen kft., maďarsko - plerixafor - 59 - immunopraeparata
plerixafor msn 20 mg/ml injekčný roztok
msn labs europe limited, malta - plerixafor - 59 - immunopraeparata
valganciclovir mylan 450 mg
mylan ireland limited, Írsko - valganciklovir - 42 - chemotherapeutica (vratane tuberkulostatik)
valdamin 450 mg
egis pharmaceuticals plc, maďarsko - valganciklovir - 42 - chemotherapeutica (vratane tuberkulostatik)
sarclisa
sanofi winthrop industrie - isatuximab - viacnásobný myelóm - antineoplastické činidlá - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
grafalon
neovii biotech gmbh, nemecko - antitymocytový imunoglobulín (králičí) - 59 - immunopraeparata
zoledronat stada
stada arzneimittel ag, nemecko - kyselina zoledrónová - 87 - varia i
zolemed 4 mg/5 ml
cande s.r.o. - kyselina zoledrónová - 87 - varia i